BELTSVILLE, Md., Aug. 10 /PRNewswire-FirstCall/ -- Spherix Incorporated has signed an agreement with Anaclim, LLC to conduct the U.S. portion of its Phase 3 clinical trial on the use of Naturlose(R) as a treatment for Type 2 diabetes. The trial is being split into portions conducted in Australia and in the United States to cover all required demographic groups. Anaclim is the only dedicated, full service, minority- focused contract research organization in the U.S.
Gleneagles CRC, a major clinical research and drug development company based in Singapore, was earlier selected to conduct the main part of the trial in Australia, with patient recruitment slated to start by the end of 2006. Anaclim will conduct the portion of the phase 3 trial that covers other demographic groups in the U.S.
Spherix President and CEO Richard Levin said, “The signing of Anaclim completes the team we need to carry out the whole Phase 3 trial. If the trial is successful, Spherix will submit a new drug application to the FDA. We have been careful to assemble a team that has the qualifications, experience, and resources to do this important job right. Now the real work begins.”
Rex Alexander, Vice President of Clinical Operations for Anaclim said, “We are excited and looking forward to this opportunity to partner with Spherix in the conduct of clinical research that could offer promising alternative treatment for a disease that continues to grow at an alarming rate in the U.S.”
Anaclim, LLC has access to a large pool of experienced minority investigators with access to minority patients, as well as to many other experienced investigators who can bring the necessary mix of patients into the Naturlose trial. Based in Indianapolis, Indiana, and established in March 2005 by former officials of Eli Lilly and Company, Anaclim provides a full range of CRO services that includes investigator identification, site management, project management, monitoring, grant management and data management.
Previous clinical trials show promise for Naturlose as a treatment for Type 2 diabetes. These studies indicated that Naturlose had a controlling long-term effect on the disease. Tagatose taken before the consumption of glucose produced a blunting effect on the otherwise normally expected rise in blood glucose. In addition, over a one-year trial, all subjects lost weight at physician-approved rates along with a significant increase in the desirable type of cholesterol, HDL. Diabetes is debilitating, widespread, and growing, now affecting more than 18.2 million people in the United States and 170 million people worldwide. Type 2 diabetes is the most common form of the disease.
Certain statements contained herein are “forward looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on March 3, 1999.
Under its motto, “A World of Solutions,” Spherix’s mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in information technology, knowledge management, and biotechnology.
Spherix’s Internet address is http://www.spherix.com.
Spherix Incorporated
CONTACT: Spherix Incorporated Investor Relations, +1-301-419-7877,info@spherix.com
Web site: http://www.spherix.com/
